NIOX GroupCSSPF 77 Market Cap is $323.27 Mil as of Jun. 24, 2026. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 866 Medical Devices & Instruments companies, NIOX Group ranks better than 63.28% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). NIOX Group's share price for the quarter that ended in Dec. 2025 was $0.92. NIOX Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 417.90 Mil. Therefore, NIOX Group's market cap for the quarter that ended in Dec. 2025 was $384.47 Mil.
NIOX Group's quarterly market cap
increased
from Dec. 2024 ($298.49 Mil) to Jun. 2025 ($384.02 Mil) and
increased
from Jun. 2025 ($384.02 Mil) to Dec. 2025 ($384.47 Mil).
NIOX Group's annual market cap
declined
from Dec. 2023 ($322.80 Mil) to Dec. 2024 ($298.49 Mil) but then
increased
from Dec. 2024 ($298.49 Mil) to Dec. 2025 ($384.47 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. NIOX Group's Enterprise Value for Today is $298.24 Mil.
NIOX Group (OTCPK:CSSPF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
NIOX Group Market Cap Related Terms
NIOX Group Market Cap Historical Data
* Premium members only.
The historical data trend for NIOX Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Market Cap distribution charts can be found below:
* The bar in red indicates where NIOX Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
NIOX Group's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Market Cap of $323.27 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #318 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 36.7%.
Is NIOX Group's Market Cap too high?
NIOX Group's current Market Cap is $323.27 Mil. The Medical Devices & Instruments industry median Market Cap is 122.09. NIOX Group's value of $323.27 Mil is 164.8% above this industry median. Based on the distribution chart, NIOX Group ranks #318 out of 866 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #318 out of 866 companies for Market Cap. This puts NIOX Group in the upper half of its industry. The industry median Market Cap is 122.09. NIOX Group's value of $323.27 Mil is 164.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 122.09, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Market Cap of $323.27 Mil is 164.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 122.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Market Cap is $323.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current Market Cap is $323.27 Mil and 164.8% above the Medical Devices & Instruments industry median of 122.09. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Market Cap is $323.27 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Market Cap: $323.27 Mil
GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
Industry Position: 164.8% above the Medical Devices & Instruments median (#318 of 866)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
